← Back to Search

Monoclonal Antibodies

NPX887 Treatment for Cancer

Phase 1

Recruiting

Research Sponsored by NextPoint Therapeutics, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Histologically or cytologically confirmed recurrent, metastatic solid tumor refractory to standard of care therapy in specified indications

Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from first dose up to 24 months

Awards & highlights

Study Summary

"This trial is testing a new antibody called NPX887 in cancer patients. The study wants to find out if NPX887 is safe and well-tolerated in patients with cancers that have a specific

Who is the study for?

This trial is for individuals with solid tumors that test positive for a protein called HHLA-2/B7-H7. Specific eligibility details are not provided, but typically participants must be in good health aside from their cancer and meet certain medical criteria.Check my eligibility

What is being tested?

The study is testing NPX887, an antibody designed to boost the immune system's response against cancer by targeting the HHLA-2/B7-H7 protein on tumor cells. It's given as an IV infusion and doctors will determine the best dose while monitoring safety.See study design

What are the potential side effects?

Since NPX887 is new, part of this study's purpose is to learn about its side effects. They could include typical reactions related to immune-based therapies such as fatigue, fever, or allergic reactions at the infusion site.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My cancer has returned or spread and does not respond to standard treatments.

Select...

I am able to care for myself and perform daily activities.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 24 months from first dose

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 24 months from first dose

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 24 months from first dose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Incidence of discontinuations, dosing interruptions, and dose reductions

Incidence of dose limiting toxicity (DLT)

Incidence of treatment-emergent adverse events (AEs)

Secondary outcome measures

Area under the concentration curve (AUC0-24) of NPX887

Half-life in blood circulation (T1/2) of NPX887

Immunogenicity of NPX887

+2 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: NPX887 TreatmentExperimental Treatment1 Intervention

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

NextPoint Therapeutics, Inc.Lead Sponsor

1 Previous Clinical Trials

131 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are prospective patients still eligible to participate in this ongoing medical study?

"According to clinicaltrials.gov, the current status of this trial does not involve patient recruitment. The trial was initially shared on 2/1/2024 and last revised on 1/26/2024. While this study is not actively enrolling participants, it's worth noting that there are currently 2504 other trials seeking volunteers for various research studies."

Answered by AI

What are the main goals and purposes of this clinical investigation?

"The primary endpoint, to be assessed from the initial dose through a 21-day period, is the occurrence of treatment-related adverse events (AEs). Additionally, secondary endpoints will involve evaluating parameters such as the peak plasma concentration (Cmax) of NPX887 - characterized by monitoring plasma levels over time; the duration in which NPX887 remains within blood circulation (T1/2) - reflecting clearance rates from plasma; and finally, assessing immunogenic responses towards NPX887 by determining instances of anti-drug antibody presence among participants."

Answered by AI

Has the NPX887 treatment received approval from the FDA?

"The safety assessment for NPX887 Treatment is rated at 1 by our team, reflecting the early Phase 1 trial stage with limited available data supporting both its safety and efficacy."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study of NPX887 for Participants With Solid Tumors Known to Express HHLA-2/B7-H7

2024. "A Study of NPX887 for Participants With Solid Tumors Known to Express HHLA-2/B7-H7". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06240728.

All > Pflugerville Tx > Paid Studies Pasadena